Table 2.
Baseline characteristics of the 160 CTEPH patients treated with PEA, BPA (with or without MT) and with MT alone (riociguat/sildenafil).
| Variable | All patients (n = 160) | PEA (n = 31) | BPA (n = 58) | MT (n = 69) | p value |
|---|---|---|---|---|---|
| Age, years | 63.2 ± 15.4 | 50.9 ± 14.7 | 62.9 ± 15.1 | 68.9 ± 12.7 | <0.01 |
| Gender, female | 95 (59%) | 17 (55%) | 33 (57%) | 45 (65%) | 0.41 |
| History of acute pulmonary embolism | 118 (74%) | 26 (84%) | 43 (74%) | 49 (71%) | 0.29 |
| Thrombophilia | 18 (11%) | 8 (26%) | 6 (10%) | 4 (6%) | 0.01 |
| Cancer history | 17 (11%) | 1 (3%) | 6 (10%) | 10 (14%) | 0.27 |
| Splenectomy | 10 (6%) | 1 (3%) | 6 (10%) | 2 (3%) | 0.28 |
| NT-proBNP, pg/ml | 2639 ± 3926 | 1894 ± 2475 | 3005 ± 4650 | 2666 ± 3772 | 0.47 |
| 6MWT, m | 310 ± 128 | 328 ± 131 | 342 ± 142 | 280 ± 354 | 0.09 |
| WHO functional class I/II/III/IV | 0/31(19%) /110(69%) /19(12%) | 0/5(16%) /20(65%) /6(19%) | 0/11(19%) /39(67%) /8(14%) | 0/15(21%) /51(72%) /5(7%) | - |
BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension; MT, medical therapy (riociguat/sildenafil) alone; NT-proBNP, N-terminal pro-brain natriuretic peptide; PEA, pulmonary endarterectomy; WHO, World Health Organization; 6MWT, 6-minute walk test.
Data are presented as mean ± SD or count (percentage).